Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Gynecologic 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1CNS 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 4Carcinoma, Ovarian Epithelial 4Uterine Cervical Neoplasms 3Sarcoma 3Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Testicular Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Penile Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Burkitt Lymphoma 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 41Nivolumab 18atezolizumab 8Specimen Handling 7Docetaxel 7durvalumab 6Paclitaxel 6Magnetic Resonance Spectroscopy 6Ipilimumab 6Cyclophosphamide 6Carboplatin 6fludarabine 4avelumab 4Oxaliplatin 4Leucovorin 4Early Intervention, Educational 4Counseling 4Biopsy 4temsirolimus 3spartalizumab 3pazopanib 3olaparib 3lenvatinib 3cabozantinib 3aldesleukin 3Trastuzumab 3Taxes 3Sirolimus 3Psychiatric Rehabilitation 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × aflibercept × Gynecologic × Clear all
NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
59 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡